# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-061003
Filing Date
2025-04-30
Accepted
2025-04-30 16:00:05
Documents
4

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | crdf_defa14a_2025.htm | DEFA14A | 48070
2 | GRAPHIC | img232721228_0.jpg | GRAPHIC | 28154
3 | GRAPHIC | img232721228_1.jpg | GRAPHIC | 958538
4 | GRAPHIC | img232721228_2.jpg | GRAPHIC | 868121
| Complete submission text file | 0000950170-25-061003.txt |  | 2600155

Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35558 | Film No.: 25894711
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)